Company intelligence / Profile preview

InDex Pharmaceuticals

Ownership: Public · INDEX
Development stage: Phase 3

Overview

The company's lead drug candidate cobitolimod (Kappaproct) was being evaluated in a Phase III study for moderate to severe ulcerative colitis, but the program was discontinued in November 2023 after a Data Monitoring Committee advised that cobitolimod was unlikely to meet the primary endpoint

Therapeutic areas: GastroenterologyImmunology
Modalities: DNA-based immunomodulatory sequences (DIMS)antisense oligonucleotide therapeutics
Industry: Biotech

Drug pipeline

1 asset

cobitolimod

Phase 3

Indications: Ulcerative colitis

Partnerships

Previously had a license agreement with Almirall for European marketing rights to Kappaproct (signed in April 2014)

Beyond the preview

Go deeper on InDex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InDex Pharmaceuticals.